A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 21, 2012

Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug

- The first combination drug of a high-dose ARB and a long acting CCB with a powerful antihypertensive effect lasting for 24 hours in Japan -

Tokyo, Japan, December 21, 2012 – Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; President: Yoshiaki Aono; hereinafter “NBI”) and Astellas Pharma Inc. (Tokyo:4503,...

Read more about Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug
Dec 14, 2012

Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections

Read more about Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections
Dec 12, 2012

FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease

Read more about FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease
Dec 12, 2012

Beyond Patent Cliff, Towards New Beyond Patent Cliff, Towards Towards New Growth Stage with Innovative Drugs

Read more about Beyond Patent Cliff, Towards New Beyond Patent Cliff, Towards Towards New Growth Stage with Innovative Drugs
Dec 11, 2012

Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Read more about Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374
Dec 11, 2012

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Dec 10, 2012

Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology

Highest level of single agent activity observed to date for FLT3-targeted therapy in relapsed/refractory AML

Read more about Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Dec 4, 2012

AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer

BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Progra

CAMBRIDGE, Mass. and TOKYO, Japan, December 3, 2012 - AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized,...

Read more about AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer
Dec 4, 2012

Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsule

Read more about Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsule
Nov 28, 2012

AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...

Read more about AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts